NPHS1 and focal segmental glomerulosclerosis: Rituximab treatment in two patients (one with relapsing minimal change disease and one with relapsing primary FSGS), who had circulating anti-nephrin autoantibodies, led to clinical remission with a reduction in the antibody levels.